Alghanim Ghazi, Qaddoumi Mohamed G, Alhasawi Nouf, Cherian Preethi, Al-Khairi Irina, Nizam Rasheeba, Alkayal Fadi, Alanbaei Muath, Tuomilehto Jaakko, Abubaker Jehad, Abu-Farha Mohamed, Al-Mulla Fahd
Genetics and Bioinformatics Department, Dasman Diabetes Institute, Kuwait City, Kuwait.
Biochemistry and Molecular Biology Department, Dasman Diabetes Institute, Kuwait City, Kuwait.
Front Endocrinol (Lausanne). 2019 Jul 24;10:495. doi: 10.3389/fendo.2019.00495. eCollection 2019.
The family of angiopoietin-like proteins (ANGPTLs) is composed of eight ANGPTLs members that are involved in regulating various metabolic processes and have been implicated in type 2 diabetes (T2D) and obesity. ANGPTL5 is an understudied member of this family that has been suggested to regulate triglyceride metabolism with a potential role in obesity. This study was designed to investigate the expression levels of ANGPTL5 protein in the circulation of subjects with obesity and T2D. A total of 204 subjects were enrolled in this cross-sectional study, of which 95 had diagnosed T2D and 109 did not (non-T2D). Within the non-T2D group, 39 subjects were obese (BMI ≥ 30 Kg/m) and 70 were not (BMI < 30 Kg/m). Among subjects with T2D, 61 were obese and 34 were non-obese. Circulating ANGPTL5 plasma levels were measured by enzyme-linked immunosorbent assay (ELISA). In this study, we showed that ANGPTL5 levels were higher in the plasma of subjects with T2D [mean ± standard error of the mean (SEM): 5.78 ± 2.70 ng/mL] compared with individuals without T2D (mean ± SEM: 4.42 ± 2.22 ng/mL; < 0.001). Obese and non-T2D subjects had significantly higher levels of ANGPTL5 (mean ± SEM: 5.115 ± 0.366 ng/mL) compared with non-obese, non-T2D subjects (mean ± SEM: 4.02 ± 0.271 ng/mL; = 0.003). Similarly, among subjects with diagnosed T2D, those who were obese had higher ANGPTL5 plasma levels than non-obese subjects, although this difference did not reach statistical significance ( = 0.088). Correlation analyses revealed that ANGPTL5 levels positively associated with fasting plasma glucose (FPG), glycated hemoglobin (HbA1c), triglycerides (TGL), and insulin resistance as measured by HOMA-IR. our data shows for the first time that circulating ANGPTL5 levels were higher in obese individuals and those with T2D. Further analysis will be required to better understand the interaction between ANGPTL5 and other metabolic related biomarkers to shed more light on its role in diabetes and obesity.
血管生成素样蛋白(ANGPTLs)家族由八个成员组成,这些成员参与调节各种代谢过程,并与2型糖尿病(T2D)和肥胖症有关。ANGPTL5是该家族中一个研究较少的成员,有人认为它可调节甘油三酯代谢,在肥胖症中可能发挥作用。本研究旨在调查肥胖症和T2D患者循环中ANGPTL5蛋白的表达水平。共有204名受试者参与了这项横断面研究,其中95人被诊断为T2D,109人未患T2D(非T2D)。在非T2D组中,39名受试者肥胖(BMI≥30 Kg/m),70名不肥胖(BMI<30 Kg/m)。在T2D患者中,61人肥胖,34人不肥胖。通过酶联免疫吸附测定(ELISA)测量循环中ANGPTL5的血浆水平。在本研究中,我们发现,与未患T2D的个体相比,T2D患者血浆中ANGPTL5水平更高[平均值±平均标准误差(SEM):5.78±2.70 ng/mL](平均值±SEM:4.42±2.22 ng/mL;P<0.001)。与非肥胖、非T2D受试者相比,肥胖且非T2D的受试者ANGPTL5水平显著更高(平均值±SEM:5.115±0.366 ng/mL)(平均值±SEM:4.02±0.271 ng/mL;P = 0.003)。同样,在已诊断为T2D的受试者中,肥胖者的ANGPTL5血浆水平高于非肥胖者,尽管这种差异未达到统计学显著性(P = 0.088)。相关性分析显示,ANGPTL5水平与空腹血糖(FPG)、糖化血红蛋白(HbA1c)、甘油三酯(TGL)以及通过稳态模型评估胰岛素抵抗(HOMA-IR)测得的胰岛素抵抗呈正相关。我们的数据首次表明,肥胖个体和T2D患者的循环ANGPTL5水平更高。需要进一步分析,以更好地了解ANGPTL5与其他代谢相关生物标志物之间的相互作用,从而更清楚地了解其在糖尿病和肥胖症中的作用。